Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study von Ahn, Inhye E., Farooqui, Mohammed Z.H., Tian, Xin, Valdez, Janet, Sun, Clare, Soto, Susan, Lotter, Jennifer, Housel, Stephanie, Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Calvo, Katherine R., Nierman, Pia, Hughes, Thomas E., Saba, Nakhle S., Marti, Gerald E., Pittaluga, Stefania, Herman, Sarah E.M., Niemann, Carsten U., Pedersen, Lone B., Geisler, Christian H., Childs, Richard, Aue, Georg, Wiestner, Adrian

Volltext

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013 von Ribrag, Vincent, Avigan, David E., Green, Damian J., Wise‐Draper, Trisha, Posada, Juan G., Vij, Ravi, Zhu, Ying, Farooqui, Mohammed Z. H., Marinello, Patricia, Siegel, David S.

Volltext

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial von Farooqui, Mohammed Z H, DO, Valdez, Janet, PA, Martyr, Sabrina, MD, Aue, Georg, MD, Saba, Nakhle, MD, Niemann, Carsten U, MD, Herman, Sarah E M, PhD, Tian, Xin, PhD, Marti, Gerald, MD, Soto, Susan, MSN, Hughes, Thomas E, PharmD, Jones, Jade, MD, Lipsky, Andrew, MD, Pittaluga, Stefania, MD, Stetler-Stevenson, Maryalice, MD, Yuan, Constance, MD, Lee, Yuh Shan, MD, Pedersen, Lone B, Geisler, Christian H, Prof, Calvo, Katherine R, MD, Arthur, Diane C, MD, Maric, Irina, MD, Childs, Richard, MD, Young, Neal S, MD, Wiestner, Adrian, Dr

Volltext

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy von Landau, Dan A., Sun, Clare, Rosebrock, Daniel, Herman, Sarah E. M., Fein, Joshua, Sivina, Mariela, Underbayev, Chingiz, Liu, Delong, Hoellenriegel, Julia, Ravichandran, Sarangan, Farooqui, Mohammed Z. H., Zhang, Wandi, Cibulskis, Carrie, Zviran, Asaf, Neuberg, Donna S., Livitz, Dimitri, Bozic, Ivana, Leshchiner, Ignaty, Getz, Gad, Burger, Jan A., Wiestner, Adrian, Wu, Catherine J.

Volltext

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia von Bitar, Carole, Farooqui, Mohammed Z. H, Valdez, Janet, Saba, Nakhle S, Soto, Susan, Bray, Amanda, Marti, Gerald, Wiestner, Adrian, Cowen, Edward W

Volltext

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer von André, Thierry, Shiu, Kai-Keen, Kim, Tae Won, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis, Smith, Denis, Garcia-Carbonero, Rocio, Benavides, Manuel, Gibbs, Peter, de la Fouchardiere, Christelle, Rivera, Fernando, Elez, Elena, Bendell, Johanna, Le, Dung T, Yoshino, Takayuki, Van Cutsem, Eric, Yang, Ping, Farooqui, Mohammed Z.H, Marinello, Patricia, Diaz, Luis A

Volltext

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib von Sun, Clare, Nierman, Pia, Kendall, Ellen K., Cheung, Jean, Gulrajani, Michael, Herman, Sarah E.M., Pleyer, Christopher, Ahn, Inhye E., Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Gaglione, Erika M., Harris, Hailey M., Pittaluga, Stefania, Wang, Min Hui, Patel, Priti, Farooqui, Mohammed Z.H., Izumi, Raquel, Hamdy, Ahmed, Covey, Todd, Wiestner, Adrian

Volltext

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study von Niemann, Carsten U, Herman, Sarah E M, Maric, Irina, Gomez-Rodriguez, Julio, Biancotto, Angelique, Chang, Betty Y, Martyr, Sabrina, Stetler-Stevenson, Maryalice, Yuan, Constance M, Calvo, Katherine R, Braylan, Raul C, Valdez, Janet, Lee, Yuh Shan, Wong, Deanna H, Jones, Jade, Sun, Clare, Marti, Gerald E, Farooqui, Mohammed Z H, Wiestner, Adrian

Volltext

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib von Lipsky, Andrew H, Farooqui, Mohammed Z H, Tian, Xin, Martyr, Sabrina, Cullinane, Ann M, Nghiem, Khanh, Sun, Clare, Valdez, Janet, Niemann, Carsten U, Herman, Sarah E M, Saba, Nakhle, Soto, Susan, Marti, Gerald, Uzel, Gulbu, Holland, Steve M, Lozier, Jay N, Wiestner, Adrian

Volltext

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study von Mateos, Maria‐Victoria, Orlowski, Robert Z., Ocio, Enrique M., Rodríguez‐Otero, Paula, Reece, Donna, Moreau, Philippe, Munshi, Nikhil, Avigan, David E., Siegel, David S., Ghori, Razi, Farooqui, Mohammed Z. H., Marinello, Patricia, San-Miguel, Jesus

Volltext

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy von Skarzynski, Martin, Niemann, Carsten U, Lee, Yuh Shan, Martyr, Sabrina, Maric, Irina, Salem, Dalia, Stetler-Stevenson, Maryalice, Marti, Gerald E, Calvo, Katherine R, Yuan, Constance, Valdez, Janet, Soto, Susan, Farooqui, Mohammed Z H, Herman, Sarah E M, Wiestner, Adrian

Volltext

Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience von Liao, Jason J.Z., Farooqui, Mohammed Z.H., Marinello, Patricia, Hartzel, Jonathan, Anderson, Keaven, Ma, Junshui, Gause, Christine K.

Volltext

P628: UPDATED ANALYSIS OF BELLWAVE‐001: A PHASE 1/2 OPEN‐LABEL DOSE‐EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B‐CELL MALIGNANCIES von Woyach, Jennifer, Flinn, Ian W., Awan, Farrukh, Eradat, Herbert, Brander, Danielle M., Tees, Michael, Parikh, Sameer, Phillips, Tycel, Ghori, Razi, Paydar, Ima, Farooqui, Mohammed Z. H., Byrd, John C., Stephens, Deborah

Volltext

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood von Herndon, T M, Chen, S-S, Saba, N S, Valdez, J, Emson, C, Gatmaitan, M, Tian, X, Hughes, T E, Sun, C, Arthur, D C, Stetler-Stevenson, M, Yuan, C M, Niemann, C U, Marti, G E, Aue, G, Soto, S, Farooqui, M Z H, Herman, S E M, Chiorazzi, N, Wiestner, A

Volltext

Bcl‐2 level as a biomarker for 13q14 deletion in CLL von Degheidy, Heba A., Gadalla, Shahinaz M., Farooqui, Mohammed Z. H., Abbasi, Fatima, Arthur, Diane C., Bauer, Steven R., Wilson, Wyndham H., Wiestner, Adrian, Stetler‐Stevenson, M. A., Marti, Gerald E.

Volltext

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial von Usmani, Saad Zafar, Schjesvold, Fredrik, Oriol, Albert, Karlin, Lionel, Cavo, Michele, LeBlanc, Richard, Takezako, Naoki, Lim, Andrew Boon Ming, Suzuki, Kenshi, Kosugi, Hiroshi, Grigoriadis, George, Avivi, Irit, Facon, Thierry, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Karlin, Lionel, Attal, Michel, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Schjesvold, Fredrik, Waage, Anders, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Saylors, Gene, Fung, Henry, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, Yasencha, Christopher K, Houck, William

Volltext

Methodological comparison of two anti‐ZAP‐70 antibodies von Degheidy, Heba A., Venzon, David J., Farooqui, Mohammed Z. H., Abbasi, Fatima, Arthur, Diane C., Wilson, Wyndham H., Wiestner, Adrian, Stetler‐Stevenson, M. A., Marti, Gerald E.

Volltext

Improved ZAP‐70 assay using two clones, multiple methods of analysis and clinical correlation von Degheidy, Heba A., Venzon, David J., Farooqui, Mohammed Z. H., Abbasi, Fatima, Arthur, Diane C., Wilson, Wyndham H., Wiestner, Adrian, Stetler‐Stevenson, M. A., Marti, Gerald E.

Volltext

Combined normal donor and CLL: Single tube ZAP‐70 analysis von Degheidy, Heba A., Venzon, David J., Farooqui, Mohammed Z. H., Abbasi, Fatima, Arthur, Diane C., Wilson, Wyndham H., Wiestner, Adrian, Stetler‐Stevenson, M. A., Marti, Gerald E.

Volltext

Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) von Giri, Pratyush, Patil, Sushrut, Ratnasingam, Sumita, Prince, H. Miles, Milliken, Samuel, Briones Meijide, Javier, Coyle, Luke, Van Der Poel, Marjolein, Mulroney, Carolyn M., Farooqui, Mohammed Z. H., Wong, Hansen, Desai, Rajendra, Zugmaier, Gerhard, Mergen, Noemi, Cannell, Paul

Volltext